Combination treatment with EGFR inhibitor and doxorubicin synergistically inhibits proliferation of MCF-7 cells and MDA-MB-231 triple-negative breast cancer cells In Vitro
dc.contributor.author | Abrahams, Beynon | |
dc.contributor.author | Gerber, Anthonie | |
dc.contributor.author | Hiss, Donavon C. | |
dc.date.accessioned | 2024-03-14T11:51:59Z | |
dc.date.available | 2024-03-14T11:51:59Z | |
dc.date.issued | 2024 | |
dc.description.abstract | The role of the epidermal growth factor receptor (EGFR) in tumor progression and survival is often underplayed. Its expression and/or dysregulation is associated with disease advancement and poor patient outcome as well as drug resistance in breast cancer. EGFR is often overexpressed in breast cancer and particularly triple-negative breast cancer (TNBC), which currently lacks molecular targets. We examined the synergistic potential of an EGFR inhibitor (EGFRi) in combination with doxorubicin (Dox) in estrogen-positive (ER+) MCF-7 and MDA-MB-231 TNBC cell lines. The exposure of MDA-MB-231 and MCF-7 to EGFRi produced an IC₅₀ₛ of 6.03 µM and 3.96 µM, respectively. Dox induced MDA-MB-231 (IC₅₀ 9.67 µM) and MCF-7 (IC₅₀ 1.4 µM) cytotoxicity. Combinations of EGFRi-Dox significantly reduced the IC₅₀ in MCF-7 (0.46 µM) and MBA-MB 231 (0.01 µM). Synergistic drug interactions in both cell lines were confirmed using the Bliss independence model. Pro-apoptotic Caspase-3/7 activation occurred in MCF-7 at 0.1–10 µM of EGFRi and Dox single treatments, whilst 1 μM Dox yielded a more potent effect on MDA-MB-231. EGFRi and Dox individually and in combination downregulated the EGFR gene expression in MCF-7 and MDA-MB-231 (p < 0.001). This study demonstrates EGFRi’s potential for eliciting synergistic interactions with Dox, causing enhanced growth inhibition, apoptosis induction, and downregulation of EGFR in both cell lines. | |
dc.description.version | Publisher's version | |
dc.identifier.citation | Abrahams, B., Gerber, A., & Hiss, D. C. (2024). Combination treatment with EGFR inhibitor and doxorubicin synergistically inhibits proliferation of MCF-7 cells and MDA-MB-231 triple-negative breast cancer cells In Vitro. International Journal of Molecular Sciences, 25(5), 3066. https://doi.org/10.3390/ijms25053066 | |
dc.identifier.issn | 1661-6596 (print) | |
dc.identifier.issn | 1422-0067 (online) | |
dc.identifier.uri | https://doi.org/10.3390/ijms25053066 | |
dc.identifier.uri | http://hdl.handle.net/11660/12466 | |
dc.language.iso | en | |
dc.publisher | MDPI | |
dc.rights.holder | Author(s) | |
dc.rights.license | https://www.mdpi.com/about/openaccess | |
dc.subject | breast cancer | |
dc.subject | triple-negative breast cancer (TNBC) | |
dc.subject | doxorubicin (Dox) | |
dc.subject | epidermal growth factor receptor (EGFR) inhibitor (EGFRi) | |
dc.subject | growth inhibition | |
dc.subject | drug combination | |
dc.subject | synergistic interactions | |
dc.subject | Bliss independence | |
dc.title | Combination treatment with EGFR inhibitor and doxorubicin synergistically inhibits proliferation of MCF-7 cells and MDA-MB-231 triple-negative breast cancer cells In Vitro | |
dc.type | Article |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Abrahams_Combination treatment with EGFR inhibitor_2024.pdf
- Size:
- 2.48 MB
- Format:
- Adobe Portable Document Format
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.63 KB
- Format:
- Item-specific license agreed upon to submission
- Description: